Pear Therapeutics Projects Growing Adoption Of Prescription Digital Therapeutics Will Raise Revenue To $22 Million, Up From $4.2 Million In 2021

Pear Therapeutics, Inc. anticipates that, due to increasing acceptance of prescription digital therapeutics (PDTs), it will earn $22 million in revenue during 2022. The projection was released in an investor statement issued on May 16, 2022, reporting Pear Therapeutics, Inc.'s first quarter 2022 performance. For the fiscal year ending December 31, 2021, Pear reported revenue of $4.2 million with more than 14,000 prescriptions written. During the first quarter of 2022, Pear reported revenue was $2.7 million, with more than 9,200 total prescriptions written. The company's revenue has been increasing steadily from $376,000 in . . .